Stem cells from Umbilical Cord Blood (UCB) have emerged as an alternative to bone marrow transplants, providing an easily obtainable and readily available source of treatment. UCB transplants may result in a lower incidence of transplant complications. This is probably because the cells have not yet developed the features that can be recognized and attacked by the recipient's immune system. $CIHN
(0)
(0)
BioStem Technologies, Inc. (BSEM) Stock Research Links